Drug Trial Radar · NCT02530905
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Last checked: Nov 20, 2026Latest source record: May 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Oct 8, 2015
Primary completion
Oct 3, 2018
Study completion Oct 3, 2018
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human dose-titration and open-label extension study to assess safety, tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 45 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
SRP-4045Drug
SRP-4045 solution for IV infusion.
PlaceboDrug
SRP-4045 placebo-matching solution for IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to Week 148
- Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to Week 148
- Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to Week 148
- Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEsTime frame: Baseline up to Week 148
- Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)Time frame: Baseline up to Week 148
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Kennedy Krieger Institute
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.